Protocol: Screening of Genetic Susceptibility Genes for Breast Cancer Patients and Establishment of Genetic High-Risk Populations Cohort in East China Communities
Zezhou Wang,Sanjian Yu,Xiaoshuang Feng,Xia Qiu,Hui Ji,Hailin Shan,Qing Shao,Heng Xia,Feng Cao,Jun Li,Cuixia Fu,Liqin Chen,Xiaofang Lu,Tingting Su,Qianqian Yu,Shengqun Hou,Honglian Wang,Yun Liu,Ying Zheng,Zhimin Shao,Zhen Hu
DOI: https://doi.org/10.21037/pcm-22-36
2021-01-01
Precision Cancer Medicine
Abstract:Background: BRCA1 and BRCA2 genes have been proven to be genetic susceptibility genes for breast cancer. Their mutations are closely related to hereditary breast cancer, and can also increase the risk of other cancers. Several studies have been conducted to examine the distribution and prevalence of BRCA1 and BRCA2 mutations as well as the penetrance of breast cancer in BRCA1/2 mutation carriers among different populations. However, most studies conducted among Chinese were hospital-based research, whichmay not reflect the real epidemiology in the population. In order to fill the gaps in community research, this study aims to screen genetic susceptibility genes of breast cancer patients in the Chinese community and establish a cohort of genetic high-risk populations. Methods: This is a multisite, prospective, cohort study which has been ongoing in 3 provinces of eastern China since 2019. Up to 5,000 breast cancer survivors will conduct BRCA1, BRCA2, PTEN, CHEK2, and PALB2 genetic susceptibility genes testing, provide clinical and genetic information and family history. Participants were followed up based on the results. Discussion: This is the first study of breast cancer and other common malignancies penetrance and genetic susceptibility gene mutation carrying possibility which is based on community breast cancer data. It is superior to data from hospitals and high-risk clinics. The establishment of a mutation prediction model suitable for the Chinese population still has high socio-economic value. Trial Registration: This study is registered at ClinicalTrials.gov. (Registration number NCT04265937).